Showing 3651-3660 of 7324 results for "".
- Vitiligo Linked to Elevated Risk of Herpes Zoster: Cohort Studyhttps://practicaldermatology.com/news/vitiligo-linked-to-elevated-risk-of-herpes-zoster-study-finds/2485328/A new cohort study from Taiwan indicated vitiligo is independently associated with a heightened risk of herpes zoster (HZ), with systemic immunosuppressive therapies compounding the risk further. Using data from Taiwan's Longit
- Analysis Suggests Possible 'Oral–Gut–Skin Axis' in HShttps://practicaldermatology.com/news/analysis-suggests-possible-oralgutskin-axis-in-hs/2485169/New microbiome research comparing acne and hidradenitis suppurativa (HS) across multiple anatomical sites shows unique microbial signatures that may aid researchers in explaining the chronic HS phenotype. The study authors ana
- Discrimination, Language Gaps Undermine HS Care for Latine Adults: Analysishttps://practicaldermatology.com/news/latine-patients-with-hs-face-barriers-in-pain-and-wound-care-study-finds-discrimination-language-gaps-undermine-hs-care-for-latine-adults/2485130/Latine patients with hidradenitis suppurativa (HS) continue to face barriers to care, according to a qualitative study published in JAMA Dermatology. Study researchers analyzed transcripts from semistructured interviews
- Study Links BMI and IBD Causally to Hidradenitis Suppurativahttps://practicaldermatology.com/news/mendelian-randomization-study-links-bmi-and-ibd-causally-to-hidradenitis-suppurativa/2485068/A new mendelian randomization (MR) analysis provides genetic evidence supporting a causal role for elevated body mass index (BMI) and inflammatory bowel disease (IBD) in hidradenitis suppurativa (HS). Study researchers used gen
- Small Case Series Shows Promise for Topical Roflumilast in HS Treatmenthttps://practicaldermatology.com/news/topical-roflumilast-shows-early-promise-for-mild-hs-in-case-series/2485022/A prospective case series published in JAAD Case Reports suggests that once-daily topical roflumilast 0.3% cream may be a promising off-label treatment for mild hidradenitis suppurativa (HS).
- Isotretinoin Slows Growth Rate in Teens, But Final Height Unchangedhttps://practicaldermatology.com/news/isotretinoin-slows-growth-rate-in-teens-but-final-height-unchanged/2484962/Adolescents treated with isotretinoin for acne may experience temporary reductions in height velocity, but the medication does not appear to impact final adult height, according to a new retrospective cohort study published in the
- Most Insurers Cover Botulinum Toxin for Axillary Hyperhidrosis: Analysishttps://practicaldermatology.com/news/most-insurers-cover-botulinum-toxin-for-axillary-hyperhidrosis-analysis/2484933/A new cross-sectional study published in the Journal of Drugs in Dermatology finds that while botulinum toxin is broadly covered by private insurers for the treatment of primary axillary hyperhidrosis, access barriers due to
- Smoking, PROs, and Attrition May Skew HS Study Outcomes: Commentaryhttps://practicaldermatology.com/news/smoking-pros-and-attrition-may-skew-hs-study-outcomes/2484927/A letter to the editor published in JAAD provided commentary and presented additional opportunities for further research on adalimumab and the effects of smoking on patient response while treating hidradenitis suppurativa (HS).
- Study: Tirzepatide Shows Early Efficacy in Hidradenitis Suppurativahttps://practicaldermatology.com/news/study-tirzepatide-shows-early-efficacy-in-hidradenitis-suppurativa/2484716/New research shows dual GLP-1/GIP inhibitor tirzepatide, a dual GLP-1/GIP receptor agonist currently approved for type 2 diabetes and obesity, may offer a novel therapeutic option for patients with moderate-to-severe hidradenitis suppurativa (HS), according to a sm
- Clascoterone 5% Solution Achieves Hair Regrowth in Large AGA Studyhttps://practicaldermatology.com/news/clascoterone-5-solution-acheives-hair-regrowth-in-large-aga-study/2484730/Cosmo Pharmaceuticals N.V. has reported phase 3 results from its two pivotal trials—Scalp 1 (NCT05910450) and Scalp 2 (NCT05914805)—evaluating clascoterone 5% topical solution for male androgenetic alopecia (AGA). According t